Viral envelope fails to deliver?

摘要

On 17 June 1994, the National Institutes of Health announced that it would continue — but not expand — clinical trials with two vaccines against the human immunodeficiency virus (HIV), which use recombinant viral gp 120 subunits to raise an immunity to the virus. To some this decision was viewed as a major setback, given the resources that had been expended in the development and testing of these vaccines. But to others, who felt that to test products with questionable promise was risky, unjustifiably costly, and would have a negative effect on future vaccine trials, this outcome was more satisfying. These events highlight a continuing struggle to establish standards for a vaccine that are acceptable to scientists, vaccine developers, government officials and the communities affected by such trials.